These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 15784157)

  • 21. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.
    Keck PE; Strakowski SM; McElroy SL
    J Clin Psychiatry; 2000; 61 Suppl 3():4-9. PubMed ID: 10724127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discriminant cognitive factors in responder and non-responder patients with schizophrenia.
    Stip E; Lussier I; Ngan E; Mendrek A; Liddle P
    Eur Psychiatry; 1999 Dec; 14(8):442-50. PubMed ID: 10683630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of side-effects and complications caused by atypical neuroleptics on the effectiveness of therapy in patients with schizophrenia].
    Danilov DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(3):48-55. PubMed ID: 20517226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia.
    Riedel M; Müller N; Spellmann I; Engel RR; Musil R; Valdevit R; Dehning S; Douhet A; Cerovecki A; Strassnig M; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Oct; 257(7):402-12. PubMed ID: 17629725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():3-9. PubMed ID: 9766613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review.
    Thornton AE; Van Snellenberg JX; Sepehry AA; Honer W
    J Psychopharmacol; 2006 May; 20(3):335-46. PubMed ID: 16174678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
    J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
    Swartz MS; Perkins DO; Stroup TS; Davis SM; Capuano G; Rosenheck RA; Reimherr F; McGee MF; Keefe RS; McEvoy JP; Hsiao JK; Lieberman JA;
    Am J Psychiatry; 2007 Mar; 164(3):428-36. PubMed ID: 17329467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.
    Agid O; Arenovich T; Sajeev G; Zipursky RB; Kapur S; Foussias G; Remington G
    J Clin Psychiatry; 2011 Nov; 72(11):1439-44. PubMed ID: 21457676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.
    Lambert M; Haro JM; Novick D; Edgell ET; Kennedy L; Ratcliffe M; Naber D
    Acta Psychiatr Scand; 2005 Mar; 111(3):232-43. PubMed ID: 15701108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
    Goff DC; Lamberti JS; Leon AC; Green MF; Miller AL; Patel J; Manschreck T; Freudenreich O; Johnson SA
    Neuropsychopharmacology; 2008 Feb; 33(3):465-72. PubMed ID: 17487227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds.
    Weickert TW; Goldberg TE; Marenco S; Bigelow LB; Egan MF; Weinberger DR
    Neuropsychopharmacology; 2003 Aug; 28(8):1491-500. PubMed ID: 12799617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects.
    Woodward ND; Purdon SE; Meltzer HY; Zald DH
    Schizophr Res; 2007 Jan; 89(1-3):211-24. PubMed ID: 17059880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
    Sacchetti E; Valsecchi P; Parrinello G;
    Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
    Kinon BJ; Liu-Seifert H; Adams DH; Citrome L
    J Clin Psychopharmacol; 2006 Dec; 26(6):632-7. PubMed ID: 17110821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
    Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
    Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
    Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
    J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
    Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.
    Sharma T; Hughes C; Soni W; Kumari V
    Psychopharmacology (Berl); 2003 Sep; 169(3-4):398-403. PubMed ID: 12845415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.